A Double-Blind, Randomized, Placebo-Controlled, 3-Period, Single Dose Crossover Study to Evaluate the Safety, Tolerability, and Blood Pressure Effect of an Oral Dose of Sumatriptan Alone and in Combination With MK0974 [telcagepant] in Migraine Patients

Trial Profile

A Double-Blind, Randomized, Placebo-Controlled, 3-Period, Single Dose Crossover Study to Evaluate the Safety, Tolerability, and Blood Pressure Effect of an Oral Dose of Sumatriptan Alone and in Combination With MK0974 [telcagepant] in Migraine Patients

Completed
Phase of Trial: Phase I

Latest Information Update: 15 May 2017

At a glance

  • Drugs Telcagepant (Primary) ; Sumatriptan
  • Indications Migraine
  • Focus Pharmacodynamics
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 22 Jul 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top